Free Trial

Magenta Therapeutics (MGTA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
376,000 shs
Average Volume
848,835 shs
Market Capitalization
$42.44 million
P/E Ratio
Dividend Yield
Price Target
MGTA stock logo

About Magenta Therapeutics Stock (NASDAQ:MGTA)

Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

MGTA Stock News Headlines

Magenta Medical Closes $105M Financing Led by Novo Holdings
Brace Yourself: Experts calling for Bitcoin to hit $100k
For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.
Brace Yourself: Experts calling for Bitcoin to hit $100k
For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.
PSTX Poseida Therapeutics, Inc.
DNTH Dianthus Therapeutics, Inc.
German streamer Joyn lands on Magenta TV
See More Headlines
Receive MGTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.23 per share


Free Float
Market Cap
$42.44 million
Not Optionable
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Stephen F. Mahoney J.D. (Age 51)
    MBA, Pres, Chief Financial & Operating Officer and Treasurer
    Comp: $637.21k
  • Shan Wu
    Head of Investor Relations
  • Mr. Thomas W. Beetham J.D. (Age 53)
    MBA, Chief Legal Officer & Sec.
  • Ms. Catherine Monaghan
    Head of Clinical Devel. Operations
  • Mr. Jim Haney
    Sr. Director of Investor Relations

MGTA Stock Analysis - Frequently Asked Questions

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics, Inc. (NASDAQ:MGTA) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.02.

When did Magenta Therapeutics' stock split?

Magenta Therapeutics's stock split on Thursday, September 7th 2023. The 2-1 split was announced on Thursday, September 7th 2023. The newly minted shares were distributed to shareholders after the closing bell on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Jason Gardner's approval rating as Magenta Therapeutics' CEO?

3 employees have rated Magenta Therapeutics Chief Executive Officer Jason Gardner on Jason Gardner has an approval rating of 60% among the company's employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When did Magenta Therapeutics IPO?

Magenta Therapeutics (MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What other stocks do shareholders of Magenta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE) and Aldeyra Therapeutics (ALDX).

This page (NASDAQ:MGTA) was last updated on 7/23/2024 by Staff

From Our Partners